bupropion and phentermine

bupropion has been researched along with phentermine in 30 studies

Research

Studies (30)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (3.33)29.6817
2010's25 (83.33)24.3611
2020's4 (13.33)2.80

Authors

AuthorsStudies
Glen, RC; Lowe, R; Mitchell, JB1
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Li, Z; Maggard, M; Maglione, M; Mojica, WA; Morton, SC; Shekelle, PG; Shugarman, L; Solomon, V; Suttorp, M; Tu, W1
Kaplan, LM1
Goldfine, AB; Hiatt, WR; Thomas, A1
Gosden, J; Heal, DJ; Smith, SL1
Carter, R; Mouralidarane, A; Oben, J; Ray, S; Soeda, J1
Howland, RH1
Nakazato, M; Ueno, H1
Aldhoon-Hainerová, I; Hainer, V1
Hainer, V1
Cunningham, JW; Wiviott, SD1
Citrome, L1
Rubio, MA1
Mehr, SR; Zimmerman, MP1
Dahiya, N; Kakkar, AK1
Fujioka, K1
Elias, D; Gutierrez, R; Kalyanasundar, B; Luna, A; Moreno, MG; Perez, CI; Simon, SA; Solorio, J1
Bragg, R; Crannage, E1
Megyeri, J; Nuffer, W; Trujillo, JM1
Braverman-Panza, J; Fujioka, K1
Halpern, B; Mancini, MC1
Aronne, LJ; Igel, LI; Kumar, RB; Saunders, KH1
Curry, SA1
Bersoux, S; Byun, TH; Chaliki, SS; Poole, KG1
Brown, SA; Izzy, M; Watt, KD1
Lee, SY; Tak, YJ1
Berghold, A; Horvath, K; Jeitler, K; Krenn, C; Semlitsch, T; Siebenhofer, A; Winterholer, S1
Hill, A; Levi, J; Venter, F; Wang, J1

Reviews

18 review(s) available for bupropion and phentermine

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Pharmacological and surgical treatment of obesity.
    Evidence report/technology assessment (Summary), 2004, Issue:103

    Topics: Adult; Appetite Depressants; Bupropion; Cyclobutanes; Diethylpropion; Fluoxetine; Fructose; Gastric Bypass; Gastroplasty; Humans; Lactones; Lipase; Obesity; Orlistat; Phentermine; Topiramate

2004
Pharmacologic therapies for obesity.
    Gastroenterology clinics of North America, 2010, Volume: 39, Issue:1

    Topics: Anti-Obesity Agents; Appetite Depressants; Bariatric Surgery; Benzazepines; Bupropion; Cyclobutanes; Ephedrine; Fenfluramine; Humans; Lactones; Naltrexone; Obesity; Orlistat; Phentermine; Weight Gain; Weight Loss

2010
A review of late-stage CNS drug candidates for the treatment of obesity.
    International journal of obesity (2005), 2013, Volume: 37, Issue:1

    Topics: Anti-Obesity Agents; Bupropion; Central Nervous System Stimulants; Drug Administration Schedule; Drug Approval; Drug Combinations; Drug Design; Drugs, Investigational; Female; Guidelines as Topic; Humans; Male; Naltrexone; Obesity; Patient Selection; Phentermine; Receptor, Serotonin, 5-HT2C; Risk Factors; Risk Reduction Behavior; United Kingdom

2013
Recent advancements in drug treatment of obesity.
    Clinical medicine (London, England), 2012, Volume: 12, Issue:5

    Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Clinical Trials as Topic; Drug Combinations; Fructose; Glucagon-Like Peptide 1; Humans; Lactones; Life Style; Liraglutide; Naltrexone; Obesity; Orlistat; Phentermine; Topiramate; Weight Loss

2012
[Cutting-edge of medicine; the prospects of novel anti-obesity drugs].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2014, Mar-10, Volume: 103, Issue:3

    Topics: Anti-Obesity Agents; Appetite; Appetite Depressants; Benzazepines; Benzoxazines; Bupropion; Clinical Trials as Topic; Drug Approval; Drug Combinations; Drug Discovery; Energy Metabolism; Enzyme Inhibitors; Fructose; Glucagon-Like Peptide 1; Humans; Hypothalamus; Lactones; Lipase; Liraglutide; Metabolic Syndrome; Naltrexone; Obesity; Orlistat; Phentermine; Topiramate

2014
Tolerability and safety of the new anti-obesity medications.
    Drug safety, 2014, Volume: 37, Issue:9

    Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Chemistry, Pharmaceutical; Drug-Related Side Effects and Adverse Reactions; Fructose; Glucagon-Like Peptide 1; Humans; Liraglutide; Naltrexone; Obesity; Phentermine; Topiramate

2014
Overview of new antiobesity drugs.
    Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:14

    Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Drug Combinations; Fructose; Glucagon-Like Peptide 1; Humans; Liraglutide; Naltrexone; Obesity; Phentermine; Topiramate; Weight Loss

2014
Modern obesity pharmacotherapy: weighing cardiovascular risk and benefit.
    Clinical cardiology, 2014, Volume: 37, Issue:11

    Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Cardiovascular Diseases; Clinical Trials as Topic; Drug Combinations; Fructose; Heart; Humans; Naltrexone; Obesity; Phentermine; Topiramate

2014
Drug treatment of obesity: current status and future prospects.
    European journal of internal medicine, 2015, Volume: 26, Issue:2

    Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Drug Combinations; Drug Therapy, Combination; Fructose; Humans; Lactones; Naltrexone; Obesity; Orlistat; Phentermine; Topiramate

2015
Safety and tolerability of medications approved for chronic weight management.
    Obesity (Silver Spring, Md.), 2015, Volume: 23 Suppl 1

    Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Delayed-Action Preparations; Drug-Related Side Effects and Adverse Reactions; Drugs, Investigational; Fructose; Glucagon-Like Peptide 1; Humans; Liraglutide; Naltrexone; Obesity; Phentermine; Topiramate; United States; United States Food and Drug Administration; Weight Loss

2015
A Comparison of New Pharmacological Agents for the Treatment of Obesity.
    The Annals of pharmacotherapy, 2016, Volume: 50, Issue:5

    Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Clinical Trials, Phase III as Topic; Drug Combinations; Fructose; Humans; Liraglutide; Naltrexone; Obesity; Phentermine; Topiramate; Weight Loss

2016
Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release.
    Expert opinion on drug safety, 2017, Volume: 16, Issue:1

    Topics: Animals; Anti-Obesity Agents; Bupropion; Delayed-Action Preparations; Drug Combinations; Fructose; Humans; Naltrexone; Obesity; Phentermine; Topiramate

2017
Practical Use of Pharmacotherapy for Obesity.
    Gastroenterology, 2017, Volume: 152, Issue:7

    Topics: Androgens; Anti-Obesity Agents; Antidepressive Agents; Antihypertensive Agents; Antipsychotic Agents; Appetite Depressants; Benzazepines; Bupropion; Drug Combinations; Fructose; Humans; Hypoglycemic Agents; Hypogonadism; Lactones; Liraglutide; Naltrexone; Obesity; Orlistat; Phentermine; Testosterone; Topiramate; Weight Gain

2017
Pharmacotherapy for obesity: What you need to know.
    Cleveland Clinic journal of medicine, 2017, Volume: 84, Issue:12

    Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Benzazepines; Bupropion; Drug Combinations; Humans; Lactones; Liraglutide; Naltrexone; Obesity; Orlistat; Phentermine

2017
Pharmacotherapy for Weight Loss in Cirrhosis and Liver Transplantation: Translating the Data and Underused Potential.
    Hepatology (Baltimore, Md.), 2021, Volume: 73, Issue:5

    Topics: Anti-Obesity Agents; Bupropion; Drug Therapy, Combination; Humans; Liraglutide; Liver Cirrhosis; Liver Transplantation; Naltrexone; Obesity; Orlistat; Phentermine; Topiramate; Translational Science, Biomedical

2021
Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
    Current obesity reports, 2021, Volume: 10, Issue:1

    Topics: Animals; Anti-Obesity Agents; Benzazepines; Bupropion; Humans; Liraglutide; Naltrexone; Obesity; Orlistat; Overweight; Phentermine; Topiramate; United States; United States Food and Drug Administration; Weight Loss

2021
Long-term effects of weight-reducing drugs in people with hypertension.
    The Cochrane database of systematic reviews, 2021, 01-17, Volume: 1

    Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Bias; Blood Pressure; Body Weight; Bupropion; Diet, Reducing; Drug Combinations; Female; Fructose; Humans; Hypertension; Lactones; Male; Middle Aged; Naltrexone; Orlistat; Phentermine; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Safety-Based Drug Withdrawals; Time; Topiramate

2021

Other Studies

12 other study(ies) available for bupropion and phentermine

ArticleYear
Predicting phospholipidosis using machine learning.
    Molecular pharmaceutics, 2010, Oct-04, Volume: 7, Issue:5

    Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine

2010
FDA-approved drug labeling for the study of drug-induced liver injury.
    Drug discovery today, 2011, Volume: 16, Issue:15-16

    Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration

2011
What cost weight loss?
    Circulation, 2012, Mar-06, Volume: 125, Issue:9

    Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Cyclobutanes; Fructose; Humans; Naltrexone; Obesity; Phentermine; Risk Assessment; Risk Factors; Topiramate; Weight Loss

2012
Therapies for obesity and medication-associated weight gain.
    Journal of psychosocial nursing and mental health services, 2013, Volume: 51, Issue:5

    Topics: Animals; Appetite Depressants; Bariatric Surgery; Benzazepines; Bupropion; Chronic Disease; Combined Modality Therapy; Diet, Reducing; Disease Models, Animal; Drug Combinations; Exercise; Fructose; Humans; Mood Disorders; Naltrexone; Obesity; Overweight; Phentermine; Psychotic Disorders; Randomized Controlled Trials as Topic

2013
Lorcaserin, phentermine topiramate combination, and naltrexone bupropion combination for weight loss: the 15-min challenge to sort these agents out.
    International journal of clinical practice, 2014, Volume: 68, Issue:12

    Topics: Benzazepines; Bupropion; Drug Combinations; Drug Prescriptions; Fructose; Humans; Naltrexone; Obesity; Phentermine; Topiramate; Weight Loss

2014
Pharmacological treatment of obesity in Europe: waiting for the arrival of the white blackbird.
    Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion, 2014, Volume: 61, Issue:10

    Topics: Anti-Obesity Agents; Appetite Depressants; Benzazepines; Bupropion; Clinical Trials as Topic; Drug Approval; Drug Combinations; Europe; Fructose; Humans; Naltrexone; Obesity; Phentermine; Product Surveillance, Postmarketing; Topiramate; United States; United States Food and Drug Administration

2014
Nonincretin drugs in later-stage development.
    The American journal of managed care, 2014, Volume: 20, Issue:1 Spec No.

    Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Drug Combinations; Drug Labeling; Drugs, Investigational; Fructose; Humans; Naltrexone; Obesity; Phentermine; United States; United States Food and Drug Administration

2014
D1 and D2 antagonists reverse the effects of appetite suppressants on weight loss, food intake, locomotion, and rebalance spiking inhibition in the rat NAc shell.
    Journal of neurophysiology, 2015, Volume: 114, Issue:1

    Topics: Action Potentials; Animals; Appetite Depressants; Benzazepines; Bupropion; Diethylpropion; Dopamine D2 Receptor Antagonists; Drug Interactions; Eating; Locomotion; Male; Nucleus Accumbens; Phentermine; Raclopride; Random Allocation; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Sleep Initiation and Maintenance Disorders; Stereotyped Behavior; Weight Loss

2015
Review of pharmacotherapy options for the management of obesity.
    Journal of the American Association of Nurse Practitioners, 2016, Volume: 28, Issue:2

    Topics: Benzazepines; Bupropion; Disease Management; Fructose; Humans; Lactones; Liraglutide; Naltrexone; Obesity; Orlistat; Phentermine; Topiramate; United States

2016
Answers to Clinical Questions in the Primary Care Management of People with Obesity: Pharmacologic Management.
    The Journal of family practice, 2016, Volume: 65, Issue:7 Suppl

    Topics: Anti-Obesity Agents; Benzazepines; Body Mass Index; Bupropion; Guidelines as Topic; Humans; Lactones; Life Style; Liraglutide; Naltrexone; Obesity; Orlistat; Overweight; Phentermine; Primary Health Care; Risk Factors; Treatment Outcome; Weight Loss

2016
Obesity Epidemic: Pharmaceutical Weight Loss.
    Rhode Island medical journal (2013), 2017, Mar-01, Volume: 100, Issue:2

    Topics: Anti-Obesity Agents; Benzazepines; Body Mass Index; Bupropion; Drug Combinations; Fructose; Humans; Lactones; Liraglutide; Naltrexone; Obesity; Orlistat; Phentermine; Weight Loss

2017
Estimated minimum prices and lowest available national prices for antiobesity medications: Improving affordability and access to treatment.
    Obesity (Silver Spring, Md.), 2023, Volume: 31, Issue:5

    Topics: Anti-Obesity Agents; Bupropion; Drug Combinations; Health Care Costs; Health Services Accessibility; Liraglutide; Naltrexone; Orlistat; Phentermine; Topiramate

2023